# A Trial of HRS-4508 Combined With Other Antitumor Therapies in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Source: https://onco.cc/trials/nct07232849/  
OnCo record `nct07232849` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of HRS-4508 tablet in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.

## Summary

A Trial of HRS-4508 Combined With Other Antitumor Therapies in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer is a phase 2 interventional study registered as NCT07232849 by Jiangsu HengRui Medicine Co., Ltd., with 100 participants planned, started 2025-12-04 and due to reach its primary completion in 2027-12. Interventions recorded: HRS-4508 tablet.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07232849
- Phase: 2
- Setting: Study on Efficacy and Safety of HRS-4508 Combined With Other Antitumor Therapies in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT07232849: https://clinicaltrials.gov/study/NCT07232849

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct07232849.json